de Oliveira, D.S.; Zaldívar, M.F.; Gonçalves, A.A.M.; Resende, L.A.; Mariano, R.M.S.; Pereira, D.F.S.; Conrado, I.S.S.; Costa, M.A.F.; Lair, D.F.; Vilas Boas, D.F.; Nakasone, E.N.; Ameno, I.S.; Goes, W.M.; Silveira-Lemos, D.; Galdino, A.S.; Nagem, R.A.P.; Dutra, W.O.; Giunchetti, R.C. New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine. Vaccines2024, 12, 271.
de Oliveira, D.S.; Zaldívar, M.F.; Gonçalves, A.A.M.; Resende, L.A.; Mariano, R.M.S.; Pereira, D.F.S.; Conrado, I.S.S.; Costa, M.A.F.; Lair, D.F.; Vilas Boas, D.F.; Nakasone, E.N.; Ameno, I.S.; Goes, W.M.; Silveira-Lemos, D.; Galdino, A.S.; Nagem, R.A.P.; Dutra, W.O.; Giunchetti, R.C. New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine. Vaccines 2024, 12, 271.
de Oliveira, D.S.; Zaldívar, M.F.; Gonçalves, A.A.M.; Resende, L.A.; Mariano, R.M.S.; Pereira, D.F.S.; Conrado, I.S.S.; Costa, M.A.F.; Lair, D.F.; Vilas Boas, D.F.; Nakasone, E.N.; Ameno, I.S.; Goes, W.M.; Silveira-Lemos, D.; Galdino, A.S.; Nagem, R.A.P.; Dutra, W.O.; Giunchetti, R.C. New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine. Vaccines2024, 12, 271.
de Oliveira, D.S.; Zaldívar, M.F.; Gonçalves, A.A.M.; Resende, L.A.; Mariano, R.M.S.; Pereira, D.F.S.; Conrado, I.S.S.; Costa, M.A.F.; Lair, D.F.; Vilas Boas, D.F.; Nakasone, E.N.; Ameno, I.S.; Goes, W.M.; Silveira-Lemos, D.; Galdino, A.S.; Nagem, R.A.P.; Dutra, W.O.; Giunchetti, R.C. New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine. Vaccines 2024, 12, 271.
Abstract
Prophylactic vaccines are important in the control of visceral leishmaniasis (VL) and as economic measures for public health. Despite the efforts to develop a vaccine against human VL caused by Leishmania infantum, none is available, and the focus has shifted to developing vaccines against canine visceral leishmaniasis (CVL). Currently, commercially available vaccines are targeted at CVL but are not effective. Different strategies have been applied in developing and improving vaccines, such as using chimeric proteins to expand vaccine coverage. The search for patents can be a way of tracking vaccines that have the potential to be marketed. In this context, the present work presents a summary of immunological aspects relevant to VL vaccine development with a focus on the composition of chimeric protein vaccines for CVL deposited in patent banks as an important approach for biotechnological development. The resulting data could facilitate the screening and selection of antigens to compose vaccine candidates with high performance against VL.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.